{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:17:39Z","timestamp":1789777059319,"version":"4.0.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.pnpbp.2018.12.009","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T11:49:31Z","timestamp":1545133771000},"page":"277-287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: A network meta-analysis"],"prefix":"10.1016","volume":"90","author":[{"given":"Dong-Dong","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Fu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yang","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao-Mao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2018.12.009_bb0005","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/11587860-000000000-00000","article-title":"Pharmacological management of treatment-resistant obsessive-compulsive disorder","volume":"25","author":"Abudy","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0010","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/JCP.0b013e318272677d","article-title":"N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Afshar","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0015","first-page":"976","article-title":"Topiramate augmentation in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Afshar","year":"2014","journal-title":"J Res Med Sci"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jpsychires.2017.06.004","article-title":"Buprenorphine augmentation improved symptoms of OCD, compared to placebo\u2014results from a randomized, double-blind and placebo-controlled clinical trial","volume":"94","author":"Ahmadpanah","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0025","doi-asserted-by":"crossref","DOI":"10.2174\/0929867325666171222163645","article-title":"A systematic review of evidence-based treatment strategies for obsessive-compulsive disorder resistant to first-line pharmacotherapy","author":"Albert","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0030","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0035","first-page":"231","article-title":"Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder","volume":"1","author":"Aouizerate","year":"2005","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0040","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1586\/ern.12.160","article-title":"Augmentation strategies in obsessive-compulsive disorder","volume":"13","author":"Arumugham","year":"2013","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0045","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1176\/ajp.154.9.1293","article-title":"Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder","volume":"154","author":"Barr","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0050","doi-asserted-by":"crossref","first-page":"716","DOI":"10.4088\/JCP.09m05266gre","article-title":"Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder","volume":"72","author":"Berlin","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0055","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","article-title":"A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder","volume":"11","author":"Bloch","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0060","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1177\/0269881111431751","article-title":"Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"26","author":"Bruno","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4088\/JCP.v65n0418","article-title":"Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial","volume":"65","author":"Bystritsky","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0070","article-title":"Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]","volume":"5","author":"Carey","year":"2005","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0075","first-page":"321","article-title":"Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable?","volume":"27","author":"Carey","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0080","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.4088\/JCP.16m11101","article-title":"Randomized, double-blind, placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"78","author":"Costa","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0924-977X(00)00065-1","article-title":"Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial","volume":"10","author":"Dannon","year":"2000","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0090","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.4088\/JCP.v65n0803","article-title":"A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors","volume":"65","author":"Denys","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0095","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.biopsych.2004.01.023","article-title":"Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder","volume":"55","author":"Denys","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0100","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.biopsych.2006.12.014","article-title":"Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors?","volume":"61","author":"Denys","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0105","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0110","author":"Dias"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0115","author":"Dias"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0120","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/JCP.0b013e3182367aee","article-title":"A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder","volume":"31","author":"Diniz","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0125","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1017\/S1461145712000740","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"16","author":"Dold","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0130","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv047","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"18","author":"Dold","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/epirev\/mxn011","article-title":"The burden of mental disorders","volume":"30","author":"Eaton","year":"2008","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euroneuro.2004.04.004","article-title":"Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"15","author":"Erzegovesi","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0145","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00004850-200507000-00005","article-title":"Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study","volume":"20","author":"Fineberg","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0150","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/01.yic.0000215083.57801.11","article-title":"Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials","volume":"21","author":"Fineberg","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0155","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S1461145799001546","article-title":"Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study","volume":"2","author":"Fux","year":"1999","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0160","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-brown obsessive compulsive scale. I. Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0165","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","article-title":"In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)","volume":"228","author":"Haghighi","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0170","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YIC.0000000000000043","article-title":"Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder","volume":"29","author":"Heidari","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0175","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0","author":"Higgins","year":"2011"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0180","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0185","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1017\/S1461145703003730","article-title":"Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"6","author":"Hollander","year":"2003","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0190","series-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry","article-title":"Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada\/Association Canadienne des troubles","volume":"14","author":"Katzman","year":"2014"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0195","first-page":"104","article-title":"Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial","volume":"11","author":"Khalkhali","year":"2016","journal-title":"Iran J Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0200","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000106474","article-title":"Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors","volume":"55","author":"Kim","year":"2007","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0205","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/JCP.0b013e318185e735","article-title":"Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study","volume":"28","author":"Kordon","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0210","doi-asserted-by":"crossref","first-page":"e1576","DOI":"10.4088\/JCP.15r10164","article-title":"Glutamatergic agents as add-on medication for the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis","volume":"77","author":"Laoutidis","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0215","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/01.blo.0000093888.12372.d9","article-title":"Association between funding source and study outcome in orthopaedic research","author":"Leopold","year":"2003","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0220","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00004714-199106000-00005","article-title":"A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy","volume":"11","author":"McDougle","year":"1991","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0225","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1176\/ajp.150.4.647","article-title":"Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder","volume":"150","author":"McDougle","year":"1993","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0230","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archpsyc.1994.03950040046006","article-title":"Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics","volume":"51","author":"McDougle","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0235","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","article-title":"A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder","volume":"57","author":"McDougle","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0240","article-title":"Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial","author":"Modarresi","year":"2017","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0245","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1017\/S1092852912000065","article-title":"Topiramate augmentation in resistant OCD: a double-blind placebo-controlled clinical trial","volume":"15","author":"Mowla","year":"2010","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0250","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/JCP.0b013e31820e3db6","article-title":"Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder a double-blind, placebo-controlled study","volume":"31","author":"Muscatello","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0255","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.pnpbp.2005.11.028","article-title":"Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines","volume":"30","author":"Pallanti","year":"2006","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0260","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1176\/appi.ajp.162.10.1957","article-title":"Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry","volume":"162","author":"Perlis","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0265","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","article-title":"Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment","volume":"132","author":"Pittenger","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0270","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4088\/JCP.14m09123","article-title":"Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial","volume":"76","author":"Pittenger","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0275","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0280","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s12325-016-0468-5","article-title":"Mavoglurant augmentation in OCD patients resistant to selective serotonin reuptake inhibitors: a proof-of-concept, randomized, placebo-controlled, phase 2 study","volume":"34","author":"Rutrick","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0285","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0290","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.psychres.2011.01.019","article-title":"A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder","volume":"189","author":"Sayyah","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0295","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/da.21996","article-title":"Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial)","volume":"29","author":"Sayyah","year":"2012","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0300","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.biopsych.2003.11.010","article-title":"A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder","volume":"55","author":"Shapira","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0305","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4088\/JCP.v66n1204","article-title":"Clinical predictors of drug nonresponse in obsessive-compulsive disorder","volume":"66","author":"Shetti","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0310","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/2045125314560739","article-title":"Aripiprazole versus quetiapine in treatment-resistant obsessive\u2013compulsive disorder: a double-blind clinical trial","volume":"5","author":"Shoja Shafti","year":"2015","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0315","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamapsychiatry.2013.1932","article-title":"Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial","volume":"70","author":"Simpson","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0320","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euroneuro.2006.07.002","article-title":"Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials","volume":"17","author":"Skapinakis","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0325","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S2215-0366(16)30069-4","article-title":"Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis","volume":"3","author":"Skapinakis","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0330","doi-asserted-by":"crossref","first-page":"E527","DOI":"10.4088\/JCP.12m08278","article-title":"Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder","volume":"74","author":"Storch","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0335","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-014-0317-5","article-title":"Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis","volume":"14","author":"Veale","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.12.009_bb0340","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/0020764009347333","article-title":"Psychosocial impact of obsessive-compulsive disorder on patients and their caregivers: a comparative study with depressive disorder","volume":"57","author":"Vikas","year":"2011","journal-title":"Int J Soc Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858461830767X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858461830767X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T16:20:06Z","timestamp":1546100406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027858461830767X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":68,"alternative-id":["S027858461830767X"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2018.12.009","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2018.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}